OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence

Pharmacogenetics and Genomics

Volumn 21, Issue 12, 2011, Pages 902-905

  Coller, Janet K ^a   Cahill, Sharon ^b   Edmonds, Carolyn ^b   Farquharson, Aaron L ^a   Longo, Marie ^b   Minniti, Rinaldo ^b   Sullivan, Thomas ^a   Somogyi, Andrew A ^a   White, Jason M ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Drug & Alcohol Services South Australia   (Australia)

Author keywords

alcohol; naltrexone treatment; OPRM1 A118G genotype

Indexed keywords

MU OPIATE RECEPTOR; NALTREXONE;

ADULT; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; WITHDRAWAL SYNDROME;

EID: 81055157808     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834c5445     Document Type: Article

References (10)

1. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25:1335-1341. (Pubitemid 32868343)
2. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Veterans affairs naltrexone cooperative study 425 group: naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345:1734-1739.
3. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al. A functional polymorphism of the m-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546-1552. (Pubitemid 41070891)
4. Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, et al. Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA cooperative study. Alcohol Clin Exp Res 2007; 31:555-563. (Pubitemid 46434892)
5. Mitchell JM, Fields HL, White RL, Meadoff TM, Joslyn G, Rowbotham MC. The Asp40 mu-opioid receptor allele does not predict naltrexone treatment efficacy in heavy drinkers. J Clin Psychopharmacol 2007; 27:112-115.
6. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65:135-144. (Pubitemid 351222547)
7. Kim SG, Kim CM, Choi SW, Jae YM, Lee HG, Son BK, et al. A mu opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology 2009; 201:611-618.
8. Coller JK, Beardsley J, Bignold J, Li Y, Merg F, Sullivan T, et al. No association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: a meta-analysis. Pharmacogen Per Med 2009; 2:9-19.
9. Rosenberg H. Clinical and laboratory assessment of the subjective experience of drug craving. Clin Psychol Rev 2009; 29:519-534.
10. Ravindranathan A, Josyln G, Robertson M, Schuckit MA, Whistler JL, White RL. Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA 2009; 106:10811-10816.